Education
About Us
Working with TipRanks
Follow Us
Elicera Therapeutics AB (SE:ELIC)
:ELIC
ELIC Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr1.19 - kr7.48
Previous CloseN/A
Volume204.65K
Average Volume (3M)613.78K
Market Cap
€250.93M
Enterprise Valuekr74.56M
Total Cash (Recent Filing)€26.40M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.82
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding48,535,545
10 Day Avg. Volume428,613
30 Day Avg. Volume613,784
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)121.48
Price to Sales (P/S)0.00
P/FCF Ratio-311.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ELIC FAQ
What was Elicera Therapeutics AB’s price range in the past 12 months?
Elicera Therapeutics AB lowest stock price was kr1.19 and its highest was kr7.48 in the past 12 months.
What is Elicera Therapeutics AB’s market cap?
Elicera Therapeutics AB’s market cap is €250.93M.
When is Elicera Therapeutics AB’s upcoming earnings report date?
Elicera Therapeutics AB’s upcoming earnings report date is Aug 27, 2025 which is in 72 days.
How were Elicera Therapeutics AB’s earnings last quarter?
Elicera Therapeutics AB released its earnings results on Apr 29, 2025. The company reported -kr0.219 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.219.
Is Elicera Therapeutics AB overvalued?
According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued.
Does Elicera Therapeutics AB pay dividends?
Elicera Therapeutics AB does not currently pay dividends.
What is Elicera Therapeutics AB’s EPS estimate?
Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elicera Therapeutics AB have?
Elicera Therapeutics AB has 48,535,545 shares outstanding.
What happened to Elicera Therapeutics AB’s price movement after its last earnings report?
Elicera Therapeutics AB reported an EPS of -kr0.219 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.887%.
Which hedge fund is a major shareholder of Elicera Therapeutics AB?
Currently, no hedge funds are holding shares in SE:ELIC
Company Description
Elicera Therapeutics AB
Elicera Therapeutics AB (ELIC) is a biotechnology company based in Sweden, specializing in the development of immuno-oncology treatments. The company focuses on creating next-generation CAR T-cell therapies and oncolytic viruses, with the aim of harnessing the body's immune system to combat cancer. Elicera's core products are centered around its proprietary platform technologies, designed to enhance the efficacy and safety of immunotherapies across various cancer indications.